Figure Gallery

Expression Pattern Search Results for plp1a

(51 figures with expression from 27 publications)

[ Show only figures with images ]
Publication	Data	Fish	Condition	Stage Range	Anatomy
Wu et al., 2025	Fig. 1	AB atp7a^hza4/hza4 (AB)	standard conditions chemical treatment by environment: copper(II) sulfate, chemical treatment by environment: elesclomol	Day 4	central nervous system myelin sheath
	Fig. 4	AB atp7a^hza4/hza4 (AB)	standard conditions chemical treatment by environment: ferrostatin-1	Day 4	central nervous system myelin sheath
	Fig. 5	AB atp7a^hza4/hza4 (AB)	standard conditions chemical treatment by environment: desferrioxamine B	Day 4	central nervous system myelin sheath
	Fig. 6	AB atp7b^hza7/hza7 (AB)	standard conditions chemical treatment by environment: RSL3	Day 4	central nervous system myelin sheath
Miyake et al., 2023	Fig. 4	WT WT + MO1-fgf22 WT + MO6-fgfr2	standard conditions	Day 4	forebrain oligodendrocyte midbrain
Raas et al., 2021	Fig. 3	abcd1^sa509/sa509	chemical treatment by environment: chloroquine	Days 7-13	whole organism
Zhang et al., 2020	Fig. 7	WT atp7b^hza7/hza7	standard conditions chemical treatment by environment: copper(2+), chemical treatment by environment: glutathione chemical treatment by environment: copper(2+)	Day 4	whole organism
	Fig. 5	WT fam168a^hza6/hza6 fam168b^hza8/hza8 WT + MO1-fam168a WT + MO1-fam168b WT + MO1-pou3f1	standard conditions	Day 4	central nervous system whole organism
	Fig. 2	WT hoxb5b^hza5/hza5 WT + MO2-hoxb5b	standard conditions chemical treatment by environment: copper(2+)	Day 4	spinal cord whole organism
	Fig. 1	WT	standard conditions chemical treatment by environment: copper(2+)	Day 4	spinal cord whole organism
	Fig. 3	WT	standard conditions chemical treatment by environment: copper(2+), chemical treatment by environment: 6-bromoindirubin-3'-oxime chemical treatment by environment: copper(2+)	Day 4	central nervous system
Miyake et al., 2017	Fig. 7	WT WT + MO1-vwc2	standard conditions	Day 4	brain oligodendrocyte
Strachan et al., 2017	Fig. 5	WT abcd1^sa509/sa509 abcd1^zc90/zc90 abcd1^sa509/+ abcd1^zc90/+	standard conditions	Protruding-mouth	whole organism
Mathews et al., 2016	Fig. 4	WT + MO1-ptena + MO4-tp53 WT + MO4-tp53 hmgcs1^vu57/vu57 + MO1-ptena + MO4-tp53 hmgcs1^vu57/vu57 + MO4-tp53	control chemical treatment by environment: sirolimus chemical treatment by environment: U0126	Day 4	hindbrain oligodendrocyte
	Fig. 2	WT hmgcs1^vu57/vu57	control chemical treatment by injection: cholesterol chemical treatment by injection: cholesterol, chemical treatment by environment: sirolimus chemical treatment by environment: sirolimus	Day 4	hindbrain oligodendrocyte
Kearns et al., 2015	Fig. 1	WT fbxw7^vu56/vu56	standard conditions	Day 4	spinal cord dorso-lateral margin spinal cord medial region spinal cord oligodendrocyte spinal cord ventral margin
	Fig. 3	WT fbxw7^vu56/vu56 mtor^{xu015Gt/xu015Gt} fbxw7^vu56/vu56; mtor^{xu015Gt/xu015Gt}	standard conditions	Day 4	spinal cord oligodendrocyte
	Fig. 2	WT mtor^{xu015Gt/xu015Gt}	standard conditions	Day 4	spinal cord oligodendrocyte
Yang et al., 2015	Fig. 5	WT dync1h1^vu76/vu76	standard conditions	Day 4	central nervous system myelin sheath
Boczonadi et al., 2014	Fig. 7	WT WT + MO1-exosc8	standard conditions	5-9 somites to Long-pec	whole organism
Mathews et al., 2014	Fig. 2	WT hmgcs1^vu57/vu57 (AB)	standard conditions	Protruding-mouth to Day 4	hindbrain oligodendrocyte spinal cord oligodendrocyte whole organism
	Fig. 4	WT hmgcs1^vu57/vu57 (AB)	control chemical treatment: atorvastatin	Protruding-mouth	hindbrain oligodendrocyte
	Fig. 5	WT hmgcs1^vu57/vu57 (AB)	control chemical treatment: drug chemical treatment: lonafarnib chemical treatment: GGTI-2133	Protruding-mouth	hindbrain oligodendrocyte
	Fig. 7	WT hmgcs1^vu57/vu57 (AB)	control chemical treatment: cholesterol chemical treatment: Ro 48-8071	Protruding-mouth	hindbrain oligodendrocyte
Miyake et al., 2014	Fig. 7	WT	standard conditions	Day 4	forebrain oligodendrocyte hindbrain oligodendrocyte